Reno, Nevada — October 10, 2025 — Leads & Copy — AI Technology Group Inc. (OTCID: AIPG) has announced its intent to acquire AVM Biotechnology Inc. (“AVM”) following the filing of an amended Form 10 with the Securities and Exchange Commission and the signing of a definitive agreement dated July 31, 2025.
According to the agreement, a newly formed subsidiary of Ai Technology Group will merge with AVM, making AVM a wholly owned subsidiary upon closing, contingent on standard closing conditions outlined in the filing. The Company plans to change its corporate name and ticker symbol post-closing, pending regulatory approval.
AVM Biotechnology is focused on commercializing “AVM0703”, a small‑molecule drug intended to combat various forms of cancer. AVM0703 is in Phase 2 human trials as a U.S. FDA investigational new drug application (IND) in relapsed/refractory non‑Hodgkin lymphoma (NHL) patients and in individual patient INDs for other blood cancers and various solid tumors. Ninety patients have been treated with the drug across Phase 1b/2 clinical trials, FDA Expanded Access, and global Compassionate Use programs, with over 250 total infusions and no cumulative toxicity observed.
AI Technology Group is conducting a private financing of at least $14 million at $2.50 per share to support AVM’s clinical development and working capital.
Investor inquiries (AVM): investor@avmbio.com
Source: AI Technology Group Inc.
